Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SIRAGUSA, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.655
EU - Europa 12.209
AS - Asia 10.158
SA - Sud America 1.788
AF - Africa 302
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 14
Totale 46.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.324
SG - Singapore 3.883
RU - Federazione Russa 2.919
IT - Italia 2.720
CN - Cina 2.432
BR - Brasile 1.423
DE - Germania 1.371
FI - Finlandia 1.067
HK - Hong Kong 1.012
VN - Vietnam 935
UA - Ucraina 932
PL - Polonia 703
GB - Regno Unito 579
FR - Francia 563
JP - Giappone 425
IE - Irlanda 389
SE - Svezia 293
IN - India 251
KR - Corea 212
BD - Bangladesh 201
CA - Canada 185
NL - Olanda 166
TR - Turchia 143
AR - Argentina 125
IQ - Iraq 104
MX - Messico 88
AT - Austria 86
RO - Romania 81
ES - Italia 76
BE - Belgio 73
CI - Costa d'Avorio 71
PK - Pakistan 69
ZA - Sudafrica 67
ID - Indonesia 66
UZ - Uzbekistan 57
EC - Ecuador 52
IR - Iran 45
VE - Venezuela 45
MA - Marocco 39
CO - Colombia 38
CL - Cile 37
SA - Arabia Saudita 37
CH - Svizzera 36
MY - Malesia 35
GR - Grecia 30
PY - Paraguay 27
EG - Egitto 26
JO - Giordania 26
AE - Emirati Arabi Uniti 23
PH - Filippine 23
KE - Kenya 22
UY - Uruguay 22
DZ - Algeria 21
LT - Lituania 21
ET - Etiopia 20
IL - Israele 20
TW - Taiwan 19
AU - Australia 17
NP - Nepal 17
CR - Costa Rica 16
KZ - Kazakistan 16
QA - Qatar 15
AL - Albania 14
CZ - Repubblica Ceca 13
TN - Tunisia 13
LB - Libano 12
OM - Oman 12
AZ - Azerbaigian 11
BG - Bulgaria 11
DO - Repubblica Dominicana 11
PE - Perù 10
DK - Danimarca 9
MD - Moldavia 9
BH - Bahrain 8
BO - Bolivia 8
EU - Europa 8
JM - Giamaica 8
MM - Myanmar 7
NZ - Nuova Zelanda 7
PT - Portogallo 7
RS - Serbia 7
AO - Angola 6
BY - Bielorussia 6
HR - Croazia 6
KG - Kirghizistan 6
SY - Repubblica araba siriana 6
TH - Thailandia 6
HU - Ungheria 5
KH - Cambogia 5
KW - Kuwait 5
PA - Panama 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
BA - Bosnia-Erzegovina 3
BF - Burkina Faso 3
CY - Cipro 3
EE - Estonia 3
HN - Honduras 3
PR - Porto Rico 3
Totale 46.106
Salva come PNG Salva come JPEG
Città #
Ashburn 2.684
Singapore 2.492
Fairfield 2.383
Chandler 1.248
Woodbridge 1.246
Houston 1.220
San Jose 1.207
Wilmington 999
Hong Kong 968
Seattle 920
Cambridge 756
Ann Arbor 633
Zgierz 599
Moscow 489
Palermo 485
Jacksonville 462
Beijing 443
Council Bluffs 443
Tokyo 397
Medford 388
Dublin 382
Helsinki 321
Frankfurt am Main 311
Ho Chi Minh City 299
Los Angeles 297
Santa Clara 297
Des Moines 294
New York 270
Lauterbourg 260
Princeton 255
Altamura 251
Dallas 250
Nanjing 237
Hanoi 235
Hefei 186
Lawrence 185
Boardman 183
San Diego 173
Milan 155
Dearborn 146
The Dalles 139
Buffalo 134
São Paulo 131
Tulsa 119
Rome 115
Chicago 88
London 88
Ludwigshafen am Rhein 88
Orem 88
Shenyang 80
Nuremberg 72
Abidjan 70
Brussels 70
Tianjin 69
Columbus 66
Nanchang 66
Phoenix 63
Amsterdam 62
Hebei 60
Stockholm 60
Warsaw 60
Seongnam 56
Changsha 52
Denver 51
Zhengzhou 49
Naperville 48
Jinan 46
Brooklyn 45
Chennai 44
Guangzhou 44
Montreal 44
Lappeenranta 43
Izmir 42
Jiaxing 42
Washington 42
Rio de Janeiro 41
Tashkent 41
San Paolo di Civitate 40
Shanghai 39
Baghdad 38
Bremen 38
Mumbai 38
Munich 38
Toronto 38
Atlanta 37
Poplar 36
Vienna 36
Falls Church 34
Redwood City 34
Da Nang 33
Verona 33
Cardiff 32
Haiphong 31
Johannesburg 31
Ningbo 31
Seoul 31
Kumar 30
Porto Alegre 30
City of London 29
Paris 28
Totale 28.752
Salva come PNG Salva come JPEG
Nome #
Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica 653
Cardiovascular events and intensity of treatment in polycythemia vera. 569
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 484
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 338
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 330
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 326
Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses 324
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 313
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 296
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 274
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity 273
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 269
Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study 260
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report 259
Health-related quality of life and psychological well-being in elderly patients with haemophilia 259
Acquired haemophilia in cancer: A systematic and critical literature review 254
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 252
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 246
Successful Treatment of Gastrointestinal Bleeding With Recombinant Factor VIIa After Kidney Transplantation in Patients With Pancytopenia. 245
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature 242
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 239
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry 239
EGFR genomic alterations in cancer: prognostic and predictive values 236
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia 236
Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study 234
Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management 232
null 231
Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry 230
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 229
Erythrocyte deformability and hemorheological profile in multiple myeloma 228
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study 225
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 225
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study 224
Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma 224
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS) 222
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 221
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 221
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 215
The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. 214
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature 214
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series 214
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. 213
Immunosenescence and lymphomagenesis 211
Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy 210
Deferral of assessment of pulmonary embolism 210
Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis 209
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 209
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 209
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 207
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy 206
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis 204
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 203
Multiple Myeloma-Derived Extracellular Vesicles Induce Osteoclastogenesis through the Activation of the XBP1/IRE1α Axis 203
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation 200
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin 200
Aspirin for preventing the recurrence of venous thromboembolism 198
Clinical implications of discordant early molecular responses in CML patients treated with imatinib 197
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up 197
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease 196
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 195
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. 194
Rivaroxaban for thromboprophylaxis in acutely ill medical patients 194
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 193
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 193
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, of both? 192
Long term outcomes of patients with cerebral vein thrombosis: a multicenter study. 192
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 192
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 191
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY 190
Cardio-oncology in multiple myeloma: is it time for a specific focus? 190
Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome 188
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. 188
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues 188
ENDOGENOUS THROMBIN POTENTIAL IN PATIENTS WITH IDIOPATHIC VENOUS THROMBOSIS 187
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. 187
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 186
Immune Cells, Cytokines, and Gut Microbiota Landscape Along Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myeloma (MM) Evolution 183
Absence of residual vein thrombosis after an episode of idiopatic deep vein thrombosis: short-term anticoagulation is safe. The extended DACUS Study 183
La profilassi chirurgica di pazienti con carenza congenita di FVII 182
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results 181
Absence of Residual Vein Thrombosis after an Episode of Idiopathic Deep Vein Thrombosis: Short-Term Anticoagulation Is Safe. The "Extended Dacus Study". 179
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 179
Gastrointestinal bleeding in patients with von Willebrand disease; how long we can wait for surgery? 178
Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins 177
Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey 176
Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again 175
Clinical history of thrombosis before diagnosis of overt myeloproliferative neoplasms in triple negative patients 174
PNEUMOCYSTIS JIROVECI PNEUMONIA IN HEMATOLOGICAL PATIENTS: A SINGLE INSTITUTION EXPERIENCE 173
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 173
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors 172
ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR FOR SURVIVAL IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA. FINAL RESULTS OF A MULTICENTER STUDY 171
Safety of plasma-derived protein C for treating disseminated intravascular coagulation in adult patients with active cancer. 170
Cardiovascular risk factor in MPN patients 169
Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. 168
D-dimer testing: advantages and limitation in emergency medicine for managing acute venous thromboembolism 167
Adverse Events in Treatment of Inherited Factor VII Deficiency: Final Analysis of the STER 167
Coexistence of Von Willebrand disease and gastrointestinal stromal tumor (G.I.S.T): Case report of a rare and challenge association 167
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits 167
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 167
The Persistance of Residual Vein Thrombosis, after an Episode of Deep Vein Thrombosis, and the Risk of New Overt Cancer and Cardiovascular Disease 166
Totale 22.305
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.555
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.555
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021722 0 0 0 0 0 0 0 0 0 0 347 375
2021/20223.008 195 591 79 130 84 160 148 155 350 396 204 516
2022/20233.912 392 733 96 405 411 619 225 307 449 45 157 73
2023/20242.042 91 286 167 280 153 356 215 88 26 58 39 283
2024/20254.822 164 268 242 459 195 164 378 365 401 518 572 1.096
2025/202618.726 1.126 794 1.020 1.592 2.081 2.789 2.562 1.985 1.690 2.591 496 0
Totale 47.281